[144] PTC Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

PTC Therapeutics (PTCT) filed a Rule 144 notice reporting a proposed sale of 15,705 common shares through Fidelity Brokerage Services on 09/11/2025 with an aggregate market value of $934,447.50. The filing lists multiple prior acquisitions of the shares primarily from restricted stock vesting in 2023 and 2024 and from option exercises/grants with specified acquisition dates and quantities. The seller represents they are unaware of undisclosed material adverse information and the form indicates no sales by the person in the prior three months.

Positive

• Full Rule 144 disclosure provided including broker, share count, aggregate value, and acquisition history
• Seller attestation that they are not aware of undisclosed material adverse information

Negative

• Insider selling of 15,705 shares valued at $934,447.50 could be perceived negatively by some investors
• No 10b5-1 plan date disclosed in the filing, so it is unclear whether the sale follows a pre-established trading plan

Insights

Securities Analyst

TL;DR: Insider plans to sell 15,705 PTCT shares worth ~$934k on 09/11/2025; acquisitions were mainly vested restricted stock and option-related.

The filing provides clear, required Rule 144 disclosure: broker, exact share count, aggregate value, and acquisition history by date and nature (restricted stock vesting and option grants). This enables investors to track insider liquidity and timing without revealing trading strategy. The absence of reported sales in the prior three months suggests this is not part of a recent frequent-trading pattern by the filer.

Corporate Governance Specialist

TL;DR: The disclosure meets compliance requirements and includes a seller representation regarding material nonpublic information.

The form includes the standard attestation that the seller does not possess undisclosed material adverse information and lists the plan for sale through a named broker. Documentation of acquisition sources (vesting and options) is helpful for transparency around insider compensation realization. No 10b5-1 plan date is provided, so it is not identified whether the sale follows a pre-established trading plan.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	15705	934447.50	79438094	09/11/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/09/2023	Restricted Stock Vesting	Issuer			934	01/09/2023	Compensation
Common	01/10/2023	Restricted Stock Vesting	Issuer			933	01/10/2023	Compensation
Common	06/06/2023	Restricted Stock Vesting	Issuer			1667	06/06/2023	Compensation
Common	06/18/2024	Restricted Stock Vesting	Issuer			1334	06/18/2024	Compensation
Common	09/11/2025	Option Granted - 02/15/2024	Issuer			10000	09/11/2025	Cash
Common	09/11/2025	Option Granted - 12/14/2018	Issuer			837	09/11/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by PTCT report?

The form reports a proposed sale of 15,705 common shares via Fidelity Brokerage Services on 09/11/2025 with an aggregate market value of $934,447.50.

Who acquired the shares being sold according to the filing?

The shares were mainly acquired through restricted stock vesting (dates in 2023 and 2024) and from option grants/exercises (notably option grants dated 02/15/2024 and 12/14/2018).

Does the filing indicate prior sales by this person in the last three months?

The filing states "Nothing to Report" for securities sold during the past three months.

Does the filer state they possess any material nonpublic information?

By signing the notice, the person represents they do not know of any material adverse information

Through which broker will the PTCT shares be sold?

The shares are to be sold through Fidelity Brokerage Services LLC at the address listed in the filing.